This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Pronzato P. Cancer-related anaemia management in the 21st century. Cancer Treat Rev 32 Suppl 2:S1–S3, 2006.
Bohlius J, Weingart O, Trelle S, et al. Cancer-related anemia and recombinant human erythropoietin–an updated overview. Nat Clin Pract Oncol 3:152–164, 2006.
Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460, 2003.
Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960–5972, 2005.
DAHANCA 10 Trial. The Cancer Letter 33, February 23, 2007.
Centers for Medicare and Medicaid Services (CMS). Available at http://www.cms.hhs.gov/home/medicare.asp. Accessed March 14, 2007.
Elliot C: Where ethics comes from and what to do about it. Hastings Cent Rep 22:28–35, 1992.
Ackerman T, Strong C: Casebook of Medical Ethics. New York, Oxford University Press, 1989.
President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Making Health Care Decisions, Vol 1. Washington, DC, Government Printing Office, 1982.
Callahan S. The role of emotion in ethical decisionmaking. Hastings Cent Rep 18:9–14, 1988.
Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083–4107, 2002.
Cancer- and treatment-related anemia v.2.2006.Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_ gls/PDF/anemia.pdf (accessed October 6, 2006), National Comprehensive Cancer Network, 2006.
Repetto L, Moeremans K, Annemans L. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Cancer Treat Rev 32 Suppl 2:S5–S9, 2006.
Beauchamp T, Childress J. The Principles of Biomedical Ethics (ed 4th ed). New York, Oxford University Press, 1992.
Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 8:149–156, 2005.
MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health 8:105–116, 2005.
Smith DH, Adams JR, Johnston SR, et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 13:1590–1597, 2002.
Laird J: Erythropoietin: can we afford to use it? Can we afford not to? Transfus Med 16:204–205, 2006.
Armour BS, Pitts MM, Maclean R, et al. The effect of explicit financial incentives on physician behavior. Arch Intern Med 161:1261–1266, 2001.
Miller TE, Sage WM. Disclosing physician financial incentives. JAMA 281:1424–30, 1999.
Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Williston Park) 16:17–24, 2002.
NHS in England. Available at http://www.nhs.uk/England/About TheNhs/History/Default.cmsx. Accessed March 6, 2007.
GAO: Medicare. Physician Incentive Payments by Prepaid Health Plans Could Lower Quality of Care. Report to the Chairman, Subcommittee on Health, Committee on Ways and Means. U.S. House of Representatives, December 1988.
Brody H. Transparency: Informed consent in primary care. Hastings Cent Rep 19, 1989.
Mehlman M. Fiduciary contracting: limitations on bargaining between patients and health care providers. Univ Pittsbg Law Rev 51:365–417, 1990.
Birgegard G, Bokemeyer C. New guidelines on anaemia management in patients with cancer: How do these affect clinical practice? Oncology 69 Suppl 2:17–21, 2005.
Engert A. Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 16:1584–1595, 2005.
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260, 2003.
Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714, 2006.
Randal J. FDA panel scrutinizes safety of anti-anemia drugs. J Natl Cancer Inst 96:1061, 2004.
Goldberg P. FDA’s ODAC to review EPO Agents in May; SEC probes Amgen delay in study disclosure. The Cancer Letter 33:1, 7–11, 2007.
Aranesp (darbepoetin alfa) Safety. Oncologic Drugs Advisory Committee, 2004.
Luksenburg H. Evolving safety issues assocaited with erythropoietin products, 2004.
R. Niesvizky AS, M. Wang, D. Weber, C. Chen, M. A. Dimopoulos, Z. Yu, Z. Yu, R. Delap, J. Zeldis, R. D. Knight. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin, 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol, 7506.
Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16:1–6, 2002.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
McKoy, J.M., Tigue, C.C., Bennett, C.L. (2008). Does Reimbursement Affect Physicians’ Decision Making? Examples from the Use of Recombinent Erythropoietin. In: Angelos, P. (eds) Ethical Issues in Cancer Patient Care Second Edition. Cancer Treatment and Research, vol 140. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-73639-6_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-73639-6_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-73638-9
Online ISBN: 978-0-387-73639-6
eBook Packages: MedicineMedicine (R0)